Development of CD46 targeted alpha theranostics in prostate cancer using <sup>134</sup>Ce/<sup>225</sup>Ac-Macropa-PEG<sub>4</sub>-YS5
Kondapa Naidu Bobba, Anil P. Bidkar, Anju Wadhwa, Niranjan Meher, Suchi Drona, Alexandre M. Sorlin, Scott Bidlingmaier, Li Zhang, David M. Wilson, Emily Chan, Nancy Greenland, Rahul Aggarwal, Henry F. VanBrocklin, Jiang He, Jonathan Chou, Youngho Seo, Bin Liu, Robert R. Flavell
Abstract
Ce PET imaging further enhances the versatility of macropa-PEG conjugates, offering a more effective and safer approach to cancer treatment. Overall, this methodology has a high potential for broader clinical applications.
Topics & Concepts
Alpha (finance)Prostate cancerRadiochemistryCancerChemistryCancer researchMedicineInternal medicinePatient satisfactionNursingConstruct validityRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and ResearchMedical Imaging and Pathology Studies